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Abstract Considerable clinical experience regarding the
long-term efficacy and safety of ruxolitinib has been gathered
since the drug was approved in the USA for patients with
intermediate or high-risk myelofibrosis (MF) in November
2011. Findings from the pivotal phase 3 COMFORT studies
showed that ruxolitinib-associated reductions in MF-related
splenomegaly and symptom burden occur rapidly and in the
majority of patients. Two- and 3-year follow-up data further
suggest that the benefits of ruxolitinib are durable and associ-
ated with a survival advantage compared with conventional
therapies. However, careful management of treatment-related
thrombocytopenia and anemia with dose modifications and
supportive care is critical to allow chronic therapy. Based on
preliminary evidence, ruxolitinib also allows spleen size and
symptom reduction before allogeneic stem cell transplantation
without negative effect on engraftment or outcomes. In recent
studies, ruxolitinib provided effective management of hema-
tologic parameters and symptoms in patients with polycythe-
mia vera refractory to or intolerant of hydroxyurea.
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Introduction
Myelofibrosis (MF) is a highly heterogeneous, chronic, BCR-
ABL1-negative myeloproliferative neoplasm (MPN) associat-
ed with progressive bone marrow fibrosis, extramedullary
hematopoiesis, excessive production of inflammatory cyto-
kines, and shortened survival [1–3]. In addition to arising de
novo as primary MF (PMF) [4], the disease also may result
from myelofibrotic transformation of other BCR-ABL1-nega-
tive MPNs, i.e., of polycythemia vera (PV) to post-PV MF or
essential thrombocythemia (ET) to post-ET MF [5]. MF pri-
marily affects elderly patients [6, 7], with an estimated annual
incidence of two to three cases per 100,000 persons in the
USA [8]. Based on the presence of specific prognostic factors,
patients are classified as low, intermediate-1, intermediate-2,
or high risk for early death [6, 9, 10]. Patients diagnosed with
low-risk MF may survive for 15 years or longer, whereas the
median life expectancy for intermediate-2 and high-risk pa-
tients is only 3 years and <2 years, respectively [9].
The clinical presentation of MF varies considerably, but
most patients have some degree of spleen enlargement and
many have spleen-related as well as constitutional symptoms.
In advanced disease, palpable spleen length is often >10 cm
[7], and debilitating spleen-related and constitutional symp-
toms are a major source of poor health-related quality of life
(QoL) [11, 12]. Another common disease manifestation is
anemia, which affects approximately 50 % of patients with
PMF [7].
The pathobiology ofMF and BCR-ABL1-negativeMPNs is
complex [13]. Although the vast majority of patients with
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MPNs have three types of essentially mutually exclusive
somatic mutations, i.e., JAK2, thrombopoietin receptor gene
(MPL), or calreticulin gene (CALR) mutations [13–15], some
may have rare mutations such as LNK mutations [16]. Addi-
tional pathogenetic complexity can result from the presence of
various mutations in epigenetic modifiers, some of which
have a negative impact on patients’ prognoses [17–20]. How-
ever, irrespective of the precise mutational status, MPNs share
distinct gene expression signatures that lead to overactivation
of the JAK-STAT signaling pathway [21•], providing a
compelling rationale for the therapeutic targeting of this
pathway in patients with MPNs across different muta-
tional backgrounds [22].
The JAK1/JAK2 inhibitor ruxolitinib to date remains the
only pharmacotherapy inMF that has been approved by the US
Food and Drug Administration (FDA). The results of two
randomized controlled phase 3 studies, COMFORT-I and
COMFORT-II, showed that ruxolitinib rapidly reduced spleno-
megaly and improved MF-related symptoms and QoL mea-
sures in patients with advanced MF compared with placebo or
best available therapy (BAT), respectively [23, 24]. Although
the COMFORT studies recruited only patients with
intermediate-2 or high-risk MF and platelet counts ≥100×
109/L, other studies confirmed that symptom and spleen re-
sponses with ruxolitinib occur across risk categories, including
intermediate-1 [25], and in patients with low platelet counts
[26]. More recently, ruxolitinib also demonstrated clinical ben-
efits in phase 2 and 3 studies of patients with advanced PV
refractory to or intolerant of hydroxyurea [27, 28].
In this review, we discuss the current and future role of
ruxolitinib in the management of patients with MPNs, includ-
ing its efficacy and safety in the long-term treatment of MF
and PV, its efficacy in the treatment of MF-associated com-
plications, and its use as pretreatment for allogeneic hemato-
poietic stem cell transplantation (alloHSCT). In addition, we
provide a brief overview of emerging therapies, including
combinations with ruxolitinib and JAK inhibitors in late clin-
ical development.
Ruxolitinib in the Management of Patients with MF
An important finding from the COMFORT studies was that
ruxolitinib provided at least some clinical benefit for the vast
majority of patients who received treatment [23, 24]. In COM-
FORT-I, all but 5 of 155 patients in the ruxolitinib arm
experienced a spleen volume reduction at week 24 [23], and
in COMFORT-II, 97 % of patients randomized to ruxolitinib
who had post-baseline data experienced a spleen size reduc-
tion at any time during the study [29••]. Further analysis of
COMFORT-I data showed that ruxolitinib was effective
across subgroups defined at baseline by MPN etiology, age,
risk status, JAK2V617F mutation status, or platelet count, or
by the presence or absence of anemia ormarked splenomegaly
[30]. Symptom and QoL improvement, which occurred in the
majority of ruxolitinib-treated patients in the COMFORT
studies, was observed for a large variety of different MF-
related symptoms and parameters defined by various symp-
tom and QoL assessment instruments, including abdominal
discomfort, pain, appetite loss, fatigue, night sweats, pruritus,
global health status/QoL, and physical, role, social, and emo-
tional functioning [31, 32].
Long-Term Efficacy and Safety in the COMFORT Studies
Durability of Spleen Volume Reductions and Symptom
Improvement
Recent 2- and 3-year follow-up data from the COMFORT
trials demonstrated the durability of ruxolitinib-mediated
spleen size reductions and QoL benefits in patients who
remain on therapy [29••, 33, 34]. In COMFORT-I, patients
randomized to ruxolitinib and remaining on therapy had a
mean percentage change from baseline in spleen volume of
−31.6 % at week 24, −34.9 % at week 96, and −34.1 % at
week 144 [33, 34]. Importantly, 100 (64.5 %) and 77 (49.7 %)
of the 155 patients randomized to ruxolitinib were still on
treatment at the time of the 2- and 3-year analysis, respectively
[33, 34]. Similarly, 45 % (66 of 146) of the patients random-
ized to ruxolitinib in COMFORT-II remained on treatment at
the time of the 3-year analysis, and those who achieved a
≥35 % reduction in spleen size (51 %) had a 50 % probability
of maintaining this level of improvement at week 144 [29••].
In COMFORT-I, 59 % of patients randomized to ruxolitinib
achieved a ≥35 % spleen volume reduction at some time
during the study [34], and those patients had a >80 % proba-
bility to still have a ≥10 % reduction at the median 2-year
follow-up (Fig. 1) [33]. Spleen volume reductions of as small
as 10 % are clinically meaningful because of their association
with effective control of symptoms and significant improve-
ment in global health status/QoL [31]. Long-term follow-up of
QoL in COMFORT-I showed that gains obtained during the
first 24 weeks, including reduction in fatigue levels and
increases in global health status/QoL and role and phys-
ical functioning, were generally maintained during long-
term follow-up [33].
Although few patients show primary clinical resistance to
ruxolitinib (lack of response), others may develop secondary
clinical resistance (loss of response) after initially responding
to ruxolitinib. A recent analysis in 41 patients found that four
and 12 of 16 patients with clinical resistance had primary
resistance (defined by the authors as a spleen volume reduc-
tion of <10 %) and secondary resistance, respectively [35].
Clinical resistance appeared not to be associated with new
mutations in the JAK2 kinase drug-binding domain, but was
significantly associated with the absence of JAK2, MPL,
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TET2, and SRSF2 mutations (P=0.003), and was more com-
mon in high-risk MF, post-ET MF, and patients with initially
smaller spleen responses [35]. In two patients with MF, re-
sponse to ruxolitinib was restored after brief withdrawal [36],
suggesting that in some patients, secondary clinical resistance
may be overcome with treatment interruptions. The effects of
retreatment with ruxolitinib in patients with MF who
interrupted treatment due to loss of response and/or adverse
events will be investigated in a planned phase 2 study
(NCT02091752).
Long-Term Safety and Management of Treatment-Related
Cytopenias
In the COMFORT studies, starting doses of 15 and 20 mg
twice daily (BID) were used, depending on whether the plate-
let count at baseline was between 100 and 200×109/L or
>200×109/L. The most common adverse effects of ruxolitinib
were dose-dependent cytopenias caused by decreases in plate-
let counts and temporary decreases in hemoglobin levels,
particularly during the first 3 months of therapy [23, 24, 37].
These adverse effects are an expected consequence of the
drug’s mechanism of action. However, thrombocytopenia
and anemia were generally managed successfully with dose
adjustments and/or brief treatment interruptions and red blood
cell transfusions (for anemia). As a result, cytopenias rarely
led to treatment discontinuation [23, 24]. Results of a
COMFORT-I post hoc analysis suggest that baseline platelet
counts <150×109/L and baseline hemoglobin <10 g/dL may
be clinically useful indicators of a likely need for dose adjust-
ments or intervention for anemia, respectively, early in the
course of therapy [38]. Timely and effective dosemanagement
is critical in keeping patients on therapy and avoiding unnec-
essary treatment interruptions and discontinuations.
Experience from COMFORT-I and other studies further sug-
gests that ruxolitinib at titrated doses of approximately 10 mg
BID may be a suitable maintenance therapy for most patients,
including those with low platelet counts at baseline [26, 37,
39, 40]. In COMFORT-I, most patients attained average daily
doses (from week 21 to week 24) of 10 mg BID or higher, and
10 mg BID was associated with clinically meaningful reduc-
tions in spleen size and symptom burden [37]. In a single-
center study of 42 patients, a dose escalation approach with a
starting dose of 5 mg BID was effective and appeared to be
associated with better hematologic tolerability than the stan-
dard dosing regimen used in the COMFORTstudies [39]. This
approach also has been shown to allow effective treatment of
patients with MF and baseline platelet counts between 50 and
100×109/L [26].
The primary results of the COMFORT studies indicated
that ruxolitinib was generally not associated with severe non-
hematologic adverse effects [23, 24], and neither trial reported
unexpected safety concerns or increasing rates of adverse
events over a 3-year follow-up period [29••, 33, 34]. However,
in clinical practice, isolated cases of serious opportunistic
infections have been reported [41–46], and there is evidence
that ruxolitinib may have immunosuppressive properties
[47–49]. Heightened vigilance is required in the treatment of
patients with a compromised immune system due to MF or
comorbidities.
The favorable safety record of ruxolitinib over a substantial
period of clinical experience is noteworthy because of the
recent safety-related termination of clinical development of
two JAK2 inhibitors. XL019 was terminated after all patients
developed central and/or peripheral neuropathy in clinical
phase 1 [50]. Fedratinib was terminated despite its efficacy
in a placebo-controlled phase 3 study [51] after its use was
linked to cases of Wernicke’s encephalopathy [52], a serious
Fig. 1 Durability of spleen volume reduction in COMFORT-I . Kaplan-
Meier curve of durability of spleen volume reduction. In patients main-
taining a ≥35 % reduction in spleen volume (dark green line), duration of
response was defined as the time from the first 35% reduction to less than
35 % reduction and 25 % increase from nadir. Among patients achieving
a 35 % reduction in spleen volume, most patients maintained a ≥10 %
reduction from baseline (light green line), with duration defined as the
time from the first 35 % reduction to less than 10 % reduction from
baseline [33]
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neurologic condition. To date, there have been no cases of
Wernicke’s encephalopathy with ruxolitinib therapy.
Effect on Survival and Natural Disease History
Although survival analyses in the COMFORT trials have been
complicated by provisions in the study design that allowed
patients in the control groups to cross over to ruxolitinib under
prespecified conditions, various survival estimates conducted
at 1, 2, and 3 years of follow-up based on the intent-to-treat
populations consistently yielded hazard ratios (HRs) that sug-
gested a 30 to 50 % survival advantage in favor of the
ruxolitinib arms (Table 1 [23, 24, 29••, 33, 34, 53]). Notably,
the COMFORT-II 3-year follow-up data provided compelling
evidence of a survival advantage for the ruxolitinib versus the
BAT arm (Table 1) [29••]. This survival advantage was inde-
pendent of the presence of prognostically detrimental muta-
tions [54]. Pooled survival data from the COMFORT studies
showed a 35 % reduction in the risk of death with
ruxolitinib versus placebo or BAT (HR, 0.65; 95 %
CI, 0.46–0.90; P=0.01) [55].
Passamonti et al. [56] compared survival from the time of
diagnosis between patients with PMF who received
ruxolitinib in COMFORT-II [24] and matched patients with
PMF who participated in the Dynamic International Prognos-
tic Scoring System (DIPSS) study [10]. The DIPSS study was
conducted before the advent of JAK inhibitor therapy, and
patients in this study received conventional therapy [10]. The
results of the comparative analysis suggested a 39% reduction
in the risk of death with ruxolitinib versus conventional ther-
apy, with median survival times of 5 years (95 % CI, 2.9–7.8)
for ruxolitinib-treated patients and 3.5 years (95 % CI, 3.0–
3.9) for the DIPSS cohort from the time of diagnosis [56].
Collectively, the available survival data suggest that
ruxolitinib may alter the natural history of MF; however, the
basis for this effect remains a matter of debate. Elevation of
specific cytokines [57], presence of specific mutations
[17–19], bone marrow fibrosis grade [58, 59], splenomegaly
[55, 60], and comorbidities [59] all may have prognostic
implications in addition to the parameters in established
scoring systems. Ruxolitinib has been shown to modify some
of these factors, including splenomegaly, symptoms and
symptom-related cytokine levels, and cachexia-related weight
loss and hypocholesterolemia [23, 24, 61], but in general does
not cause rapid or major changes in bone marrow
histomorphology and generally has no major effect on mutant
allele burden [24, 29••]. Thus, the life-prolonging effect of
ruxolitinib may be primarily a consequence of patients’ im-
provement in overall clinical status. However, a complete
resolution of bone marrow fibrosis has been documented in
two patients with post-PV MF after 168 weeks (39 months)
[62] and 17 months of ruxolitinib therapy [63]. In addition, a
preliminary report showed that long-term therapy with
ruxolitinib for up to 5 years halted or reversed bone marrow
fibrosis progression in some patients with MF compared with
a matched control group that received BAT (not including
JAK inhibitors) [64]. The observed reductions in bone mar-
row fibrosis grade were accompanied by evidence of some
improvement in the bone marrow inflammatory stromal reac-
tion and megakaryocyte morphology [65].
Effect on Clinical Manifestations Other Than Splenomegaly
and Constitutional Symptom Burden
Case reports and results from clinical studies indicate that
ruxolitinib can mitigate clinical manifestations and complica-
tions of MF besides splenomegaly and constitutional symp-
toms. For example, individual patients with MF who devel-
oped hepatomegaly after splenectomy achieved liver size
reductions of 50 to 68 % and concomitant improvement of
hepatomegaly-related symptoms [66]. In addition, normaliza-
tion of blood counts has been observed in patients who had
marked leukocytosis and thrombocytosis but no clinically
significant spleen enlargement [66].
In a study in 15 patients with intermediate- or high-risk MF
and pulmonary hypertension, treatment with ruxolitinib was
associated with statistically (P<0.05, compared with pretreat-
ment values) and clinically significant improvements in he-
matologic and cardiac parameters [67]. These improvements
were accompanied by significant reductions (P≤0.05) in IL-4,
Table 1 Overall survival in the COMFORT trials at 1, 2, and 3 years of follow-up
COMFORT-I COMFORT-II
RUX (n=155) vs. PBO (n=154) RUX (n=146) vs. BAT (n=73)
Median follow-up HR (95 % CI) P value* Median follow-up HR (95 % CI) P value*
1 year (51 weeks) [23] 0.50 (0.25–0.98) 0.04 1 year (52 weeks) [24] 0.70 (0.20–2.49)
2 years (102 weeks) [33] 0.58 (0.36–0.95) 0.03 2 years (112 weeks) [53] 0.51 (0.27–0.99) 0.041
3 years (149 weeks) [34] 0.69 (0.46–1.03) 0.067 3 years (151 weeks) [29••] 0.48 (0.28–0.85) 0.009
*P values not adjusted for multiple comparisons
BAT best available therapy, CI confidence interval, HR hazard ratio, PBO placebo, RUX ruxolitinib
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IL-6, IL-8, and TNF-α plasma levels [67]. Preliminary results
of an investigator-initiated multicenter phase 2 study of
ruxolitinib in patients with MPN-associated splanchnic vein
thrombosis suggest that ruxolitinib may reduce spleen and
liver parenchymal stiffness (as assessed by FibroScan) and
cardiac output, consistent with improvement of the splanchnic
and systemic circulation [68].
Ruxolitinib Before Allogeneic Stem Cell Transplantation
AlloHSCT remains the only potentially curable treatment for
MF, but it also remains associated with high risks of mortality
[69, 70]. Age, constitutional symptoms, and massive spleno-
megaly are considered risk factors for poor outcomes of
alloHSCT [70, 71]. A number of small retrospective studies
have evaluated the effects of ruxolitinib pretreatment on out-
comes of alloHSCT. In a study at a single institution, 14
patients received ruxolitinib therapy before alloHSCT for 2
to 12 months [72]. This resulted in a 41 % median decrease in
palpable spleen length in 9 of 11 patients with splenomegaly
and a median reduction in symptom scores of 52.5 % in 11 of
the 14 patients. Engraftment occurred in 13 patients (93 %).
After a median follow-up of 9 months, overall survival, event-
free survival, and treatment-related mortality rates were 79,
64, and 7 %, respectively.
In a German multicenter study in 22 patients, ruxolitinib
treatment before alloHSCT reduced spleen size and constitu-
tional symptoms in the majority of patients, and the estimated
1-year overall survival and disease-free survival rates were 81
and 76 %, respectively. No adverse effects of ruxolitinib
withdrawal at the start of conditioning and no negative impact
of treatment on engraftment were observed [73•]. Interesting-
ly, a significant difference in overall survival rates (P=0.02)
between patients who showed spleen responses with
ruxolitinib therapy (12/12) and those who did not (6/10) was
noted. Overall, 27 % of the patients had acute graft-versus-
host disease (GvHD) grade 3 or 4, and one patient died of
GvHD. Analysis of T cell population at day 100 after trans-
plantation suggested that ruxolitinib had no negative impact
on immune reconstitution [73•]. A recent study further pro-
vided evidence that ruxolitinib can be effective in the treat-
ment of steroid-refractory GvHD after alloHSCT by suppress-
ing the production of pro-inflammatory cytokines [74].
In a French study in 11 patients with MF, treatment with
ruxolitinib before alloHSCT reduced spleen size, was well
tolerated, and was associated with and excellent engraftment
rate. After a median of 339 days since the initiation of
ruxolitinib therapy, survival was 80 % and 6 patients (54 %)
were in complete remission [75]. However, preliminary re-
sults of an ongoing phase 2 study (JAK-ALLO,
NCT01795677) of ruxolitinib before alloHSCT in 22 patients
with MF revealed unexpected, potentially treatment-related,
serious adverse events after ruxolitinib withdrawal and
initiation of preparative chemotherapy regimen, namely tumor
lysis syndrome (n=3) and cardiogenic shock (n=3) [76].
Another phase 2 study evaluating ruxolitinib as pretreatment
for reduced-intensity alloHSCT in MF is currently recruiting
patients (NCT01790295).
Future Perspectives
Ruxolitinib-Based Combination Therapy for MF
Although ruxolitinib therapy represents a major advance in
the management of MF, its benefit has limitations, including
lack of improvement in cytopenias and other manifestations of
the marrow failure state associated with advanced MF. Avail-
able preclinical and early-phase clinical data suggest that
agents with complementary or synergistic activity may in-
clude anti-fibrotic agents such as anti-lysyl oxidase-like-
2 antibodies [77–79] and PRM-151 (recombinant human
pentraxin-2) [80], inhibitors of epigenetic dysregulation such
as histone deacetylase inhibitors [79, 81–83], other kinase
inhibitors targeting the JAK-STAT pathway [84, 85], and
hedgehog inhibitor LDE225 [86]. Ongoing studies of
ruxolitinib-based combination therapy are listed in Ta-
ble 2. Of note, a recent phase 1b dose-finding study of
ruxolitinib and panobinostat in patients with MF re-
vealed a tolerable safety profile for this combination
and encouraging spleen size reductions [87].
Although immunomodulatory drugs may be used to treat
cytopenias, they are generally associated with dose-limiting
toxicities and modest activity inMF as single therapy [88, 89].
However, they may be useful in combination with JAK inhib-
itor therapy. A number of combination studies of ruxolitinib
with anti-anemia drugs are currently underway, including a
phase 2 study of ruxolitinib plus danazol in patients with
advanced MF and anemia, a phase 2 study of ruxolitinib plus
lenalidomide in patients with MF, and a phase 1b/2
study of ruxolitinib plus pomalidomide in patients with
MF and anemia (Table 2).
Emerging Therapies for MF
Two JAK inhibitors now in phase 3 clinical development,
pacritinib and momelotinib, have shown promise in improv-
ing the management of patients with MF and low platelet
counts or anemia. Furthermore, in an ongoing investigator-
sponsored single-center study, a number of patients treated
with the telomerase inhibitor imetelstat achieved complete
morphologic and/or molecular remission [90]. However, in
March 2014, the imetelstat study was placed on partial
clinical hold by the FDA because of suspected treatment-
related hepatotoxicity [91].
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Pacritinib
Combined data from phase 2 studies showed that pacritinib, a
JAK2/FLT3 inhibitor, reduced spleen volume by ≥35 % in
43% of evaluable patients withMF and platelet counts ≤100×
109/L [92]. Analysis of changes in Common Terminology
Criteria (CTC) grade for hemoglobin levels and platelet
counts revealed improvement by 1 grade in 16 and 18 %
and worsening by 1 grade in 28 and 30 % of patients, respec-
tively. Of 57 patients who had platelet counts of ≤100×109/L
and were subject of an integrated safety analysis across phase
1 and phase 2 studies, 46 % had no CTC grade change from
baseline in hemoglobin level or platelet count [92]. These
findings suggest that pacritinib may have less of a myelosup-
pressive effect than ruxolitinib, particularly on platelets. A
phase 3 study is currently evaluating the efficacy and safety
of pacritinib versus BAT (including ruxolitinib) in patients
with MF and thrombocytopenia (NCT02055781).
Momelotinib (CYT387)
In a phase 1/2 study of the JAK1/JAK2 inhibitor momelotinib
in patients with advancedMF, 39 % of evaluable patients who
completed nine or more treatment cycles of 28 days had a
spleen response, and 46 to 100 % of patients experienced
≥50 % improvement in individual symptom scores. In addi-
tion, 68 % of previously red blood cell transfusion–dependent
patients became transfusion independent, while thrombocyto-
penia (29 %), neutropenia (5 %), and lipase elevation (4 %)
were the most common grade 3 or 4 adverse events related to
therapy [93]. The mitigating effect on anemia reported for
momelotinib is unique among JAK inhibitors and has been
proposed to result from treatment-related effects on specific
cytokines, possibly including IL-1 receptor antagonist (IL-
1RA) and IL-1β [94]. A randomized BAT-controlled (not
including ruxolitinib) phase 3 study evaluating the efficacy
and safety of momelotinib in patients with MF and anemia or
thrombocytopenia who were treated with ruxolitinib is
planned (NCT02101268). In addition, a comparative phase 3
study of momelotinib and ruxolitinib in patients with MF is
ongoing (NCT01969838).
Ruxolitinib for PV and Other BCR-ABL1-Negative
Hematologic Neoplasms
In a phase 2 study of ruxolitinib in 34 patients with advanced
PV refractory to or intolerant of hydroxyurea, treatment re-
sulted in rapid and durable clinical benefits [27]. A hematocrit
level <45 % without phlebotomy was achieved in 97 % of
patients by week 24, with a 61 % probability of maintaining
this response at week 144. Of patients with palpable spleno-
megaly at baseline, 63 % had a non-palpable spleen at week
144. In addition, ruxolitinib therapy resulted in clinically
meaningful improvement of symptoms (pruritus, night
sweats, and bone pain) and sustained reductions in white
blood cell counts in most patients. Grade ≥3 thrombocytope-
nia and grade ≥3 anemia occurred in three patients each (five
patients overall) and were managed with dose modifications
and/or treatment interruptions [27]. A preliminary report from
the RESPONSE trial (NCT01243944), a randomized open-
label phase 3 study in 222 phlebotomy-dependent patients
with PV and splenomegaly and resistance or intolerance to
hydroxyurea, indicated that 21 % of patients randomized to
ruxolitinib 10mgBID (n=110) comparedwith 1% of patients
randomized to BAT (n=112) achieved both hematocrit control
(defined as no more than one phlebotomy in the first 8 weeks
post randomization and no eligibility for phlebotomy based on
hematocrit levels from weeks 8 to 32) and a ≥35 % reduction
in spleen volume at week 32 (P<0.0001) [28]. In the
ruxolitinib and BAT arms, respectively, 60 versus 20 % of
Table 2 Ongoing trials of ruxolitinib combination therapy in MF
Clinical trial
number
Phase Combination Patients Sponsor
NCT01693601
(PRIME)
1/2 Ruxolitinib + panobinostat Intermediate-2 or high-risk MF, platelet count ≥75×109/L Mount Sinai School of
Medicine
NCT01433445 1b Ruxolitinib + panobinostat MF, platelet count >100×109/L Novartis
NCT01732445 2 Ruxolitinib + danazol Intermediate- or high-risk MF, platelet count ≥50×109/L, and
anemia (hemoglobin <10 g/dL or transfusion dependent)
Mayo Clinic
NCT01644110 1/2 Ruxolitinib + pomalidomide MF with anemia (hemoglobin <10 g/dL or transfusion dependent) University of Ulm
NCT01375140 2 Ruxolitinib + lenalidomide
(with or without prednisone)
Intermediate- or high-risk MF, platelet count ≥100×109/L MD Anderson Cancer
Center
NCT01369498 2 Ruxolitinib + GS-6624 Intermediate- or high-risk MF Gilead Sciences
NCT01981850 2 Ruxolitinib+PRM-151 Intermediate- or high-risk MF Promedior, Inc.
NCT01787552 1/2 Ruxolitinib + LDE225 Intermediate- or high-risk MF, platelet count ≥75×109/L Novartis
NCT01730248 1b Ruxolitinib + BKM120 Intermediate- or high-risk MF, platelet count ≥75×109/L Novartis
MF myelofibrosis
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patients achieved hematocrit control, 38 versus 1 % had a
≥35% reduction in spleen volume, 49 versus 5% had a ≥50%
reduction in symptom burden, and 24 versus 9 % had a
complete hematologic response. One patient treated with
ruxolitinib and 6 patients who received BAT had thromboem-
bolic events during the first 32 weeks. Grade 3 or 4 anemia
occurred in 1.8 and 0 % of patients in the ruxolitinib and BAT
arms, respectively; the corresponding percentages for grade 3
or 4 thrombocythemia were 5.5 and 3.6 %, respectively [28].
Another phase 3 study is currently investigating the efficacy
and safety of pegylated interferon-α2a versus hydroxyurea in
patients with high-risk PVor ET (NCT01259856).
Case reports suggest that ruxolitinib therapy also may benefit
patients with other chronic leukemias characterized by overac-
tive JAK-STAT signaling. Hematologic and symptom improve-
ment with ruxolitinib treatment was recently reported for two
patients with Chuvash polycythemia [95]. In addition, a patient
with chronic neutrophilic leukemia (CNL) and a point mutation
(T618I) in the colony-stimulating factor 3 receptor gene CSF3R
experienced rapid andmarked reductions in white blood cell and
absolute neutrophil counts [96]. This is consistent with preclin-
ical data showing that CNL and atypical chronic myeloid
leukemia associated with oncogenic CSF3R mutations are
sensitive to JAK inhibition [96].
Conclusion
Ruxolitinib provides rapid and durable clinical benefits in MF
that may extend beyond spleen size reduction, symptomatic
mitigation, and QoL improvement, including reducing hepa-
tomegaly or improving splanchnic thrombosis or pulmonary
hypertension. In addition, ruxolitinib therapy has been shown
to be effective in the treatment of patients with PV who are
refractory to or intolerant of hydroxyurea, and treatment re-
sults for individual cases raise the possibility that ruxolitinib
may benefit specific patients with Chuvash polycythemia or
CNL.
Ruxolitinib therapy in MF has been associated with a
survival advantage compared with conventional thera-
pies. Ruxolitinib appears to alter the natural history of
MF primarily by improving overall health status and/or
modifying risk factors, but in some patients, long-term
therapy also may halt or even reverse the progression of
bone marrow fibrosis.
Combination therapies with ruxolitinib and emerging ther-
apies are currently in development and may further improve
outcomes and/or address remaining clinical needs such as
anemia. Preliminary evidence also suggests that ruxolitinib
can be beneficial as pretreatment for alloHSCT, but further
investigation in controlled trials is necessary to thoroughly
evaluate its effect on post-transplantation outcomes.
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